A phase I trial with recombinant interferon γ (Roussel UCLAF) in advanced cancer patients

François Boue; Zulay Pastran; Marc Spielmann; Thierry Le Chevalier; Rosana Subirana; Dominique Sevin; Catherine Paoletti; Maud Brandely; Marie-Françoise Avril; Hélène Sancho-Garnier; Thomas Tursz

doi:10.1007/bf01741727

A phase I trial with recombinant interferon γ (Roussel UCLAF) in advanced cancer patients

Cancer Immunology Immunotherapy ◽

10.1007/bf01741727 ◽

1990 ◽

Vol 32 (1) ◽

pp. 67-70 ◽

Cited By ~ 8

Author(s):

François Boue ◽

Zulay Pastran ◽

Marc Spielmann ◽

Thierry Le Chevalier ◽

Rosana Subirana ◽

...

Keyword(s):

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Phase I Trial ◽

Interferon Γ ◽

Advanced Cancer Patients ◽

Recombinant Interferon

Download Full-text

First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.3009 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3009-3009 ◽

Cited By ~ 11

Author(s):

T. A. Yap ◽

A. Patnaik ◽

I. Fearen ◽

D. Olmos ◽

K. Papadopoulos ◽

...

Keyword(s):

Antitumor Activity ◽

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Phase I Trial ◽

Advanced Cancer Patients ◽

Akt Inhibitor

Download Full-text

Final results of a first-in-human phase I trial of PBI-05204, an inhibitor of AKT, FGF-2, NF-Kb, and p70S6K in advanced cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.3023 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 3023-3023 ◽

Cited By ~ 5

Author(s):

H. A. Henary ◽

R. Kurzrock ◽

G. S. Falchook ◽

A. Naing ◽

S. L. Moulder ◽

...

Keyword(s):

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Phase I Trial ◽

Advanced Cancer Patients

Download Full-text

4 “WAS IT WORTH IT?” A PILOT STUDY OF ADVANCED CANCER PATIENTS' RETROSPECTIVE PERCEPTIONS OF BENEFIT FROM PHASE I TRIAL PARTICIPATION.

Journal of Investigative Medicine ◽

10.1136/jim-55-02-04 ◽

2007 ◽

Vol 55 (2) ◽

pp. S347.4-S347

Author(s):

J. Y. Bruce ◽

F. J. Hlubocky ◽

C. K. Daugherty

Keyword(s):

Pilot Study ◽

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Phase I Trial ◽

Trial Participation ◽

Advanced Cancer Patients ◽

Retrospective Perceptions

Download Full-text

Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients

Cancer Immunology Immunotherapy ◽

10.1007/s00262-015-1711-7 ◽

2015 ◽

Vol 64 (9) ◽

pp. 1159-1173 ◽

Cited By ~ 13

Author(s):

Maria Grazia Cusi ◽

Cirino Botta ◽

Pierpaolo Pastina ◽

Maria Grazia Rossetti ◽

Elena Dreassi ◽

...

Keyword(s):

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Thymidylate Synthase ◽

Phase I Trial ◽

Advanced Cancer Patients ◽

Epitope Peptide

Download Full-text

PHASE I TRIAL OF IMMUNOMODULATORY ACTIVITIES OF HUMAN LEUKOCYTE INTERFERON IN ADVANCED CANCER PATIENTS

NK Cells and Other Natural Effector Cells ◽

10.1016/b978-0-12-341360-4.50188-8 ◽

1982 ◽

pp. 1273-1278 ◽

Cited By ~ 1

Author(s):

Jerry A. Bash ◽

James N. Woody ◽

John R. Neefe

Keyword(s):

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Phase I Trial ◽

Human Leukocyte ◽

Advanced Cancer Patients ◽

Human Leukocyte Interferon

Download Full-text

Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity

10.1158/1535-7163.targ-15-pr14 ◽

2015 ◽

Cited By ~ 5

Author(s):

Timothy A. Yap ◽

Maria J. de Miguel Luken ◽

Brent O'Carrigan ◽

Desam Roda ◽

Dionysis Papadatos-Pastos ◽

...

Keyword(s):

Antitumor Activity ◽

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Ataxia Telangiectasia ◽

Phase I Trial ◽

Preliminary Evidence ◽

Ataxia Telangiectasia Mutated ◽

Advanced Cancer Patients

Download Full-text

Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients

10.1158/1538-7445.am2015-ct323 ◽

2015 ◽

Cited By ~ 8

Author(s):

Vasiliki Michalarea ◽

David Lorente ◽

Juanita Lopez ◽

Suzanne Carreira ◽

Hasina Hassam ◽

...

Keyword(s):

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Dose Escalation ◽

Phase I Trial ◽

Parp Inhibitor ◽

Advanced Cancer Patients ◽

Akt Inhibitor

Download Full-text

Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations

10.1158/1538-7445.am2016-ct010 ◽

2016 ◽

Cited By ~ 4

Author(s):

Vasiliki Michalarea ◽

Desam Roda ◽

Yvette Drew ◽

Suzanne Carreira ◽

Brent S. O’Carrigan ◽

...

Keyword(s):

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Phase I Trial ◽

Parp Inhibitor ◽

Noninvasive Monitoring ◽

Advanced Cancer Patients ◽

Akt Inhibitor ◽

Cancer Mutations

Download Full-text

343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts)

European Journal of Cancer ◽

10.1016/s0959-8049(16)30206-4 ◽

2015 ◽

Vol 51 ◽

pp. S68 ◽

Cited By ~ 1

Author(s):

V. Michalarea ◽

J. Lopez ◽

D. Lorente ◽

S. Carreira ◽

H. Hassam ◽

...

Keyword(s):

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Phase I Trial ◽

Parp Inhibitor ◽

Advanced Cancer Patients ◽

Akt Inhibitor

Download Full-text

PHASE I STUDY OF SYSTEMIC LYMPHOKINE (LCL-LK) ADMINISTRATION IN ADVANCED CANCER PATIENTS

Human Lymphokines ◽

10.1016/b978-0-12-406080-7.50056-4 ◽

1982 ◽

pp. 633-639 ◽

Cited By ~ 1

Author(s):

Joaquim Gouveia ◽

Patricia Ribaud ◽

Antoine Goutner ◽

Georges Mathé

Keyword(s):

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Phase I Study ◽

Advanced Cancer Patients

Download Full-text